Part A - PD-1/PD-L1 blockade in cancer immunotherapy/ Part B - Evaluation of PD-1/PD-L1 immune checkpoint inhibitors in a luciferase-reporter cell-based assay
Part A: Molecules that downregulate the immune response are key during cancer treatment because they pose a mechanism to avoid immunotherapy, also called immune checkpoints. In that regard, the PD-1/PD-L1 pathway has been thoroughly studied to deepen our understanding of the function of these immun...
| Main Author: | |
|---|---|
| Format: | Thesis (University of Nottingham only) |
| Language: | English |
| Published: |
2023
|
| Subjects: | |
| Online Access: | https://eprints.nottingham.ac.uk/76035/ |